<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01142934</url>
  </required_header>
  <id_info>
    <org_study_id>TegaCHGit01</org_study_id>
    <nct_id>NCT01142934</nct_id>
  </id_info>
  <brief_title>Trial on the Efficacy of Tegaderm Chlorhexidine Gluconate (CHG) in Reducing Catheter Related Bloodstream Infections</brief_title>
  <acronym>TegaCHG</acronym>
  <official_title>A MULTICENTRE RANDOMIZED CONTROLLED CLINICAL TRIAL ON THE EFFICACY OF TEGADERM CHG IN REDUCING CATHETER RELATED BLOOD STREAM INFECTIONS</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Catholic University of the Sacred Heart</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>3M</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Fondazione C.N.R./Regione Toscana &quot;G. Monasterio&quot;, Pisa, Italy</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Catholic University of the Sacred Heart</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      TegaCHG is a multicentric randomized study aimed at evaluating the possibility that the use&#xD;
      of TegaDerm CHG dressing may reduce the incidence of catheter related blood stream infections&#xD;
      (CRBSI). It implies the comparison between the incidence of CRBSI in patients with central&#xD;
      venous catheter dressed with TegaDerm without chlorhexidine gluconate (CHG) and with CHG. The&#xD;
      primary endpoint is the occurrence of CRBSI and the secondary endpoints are:&#xD;
&#xD;
      catheter colonization (growth of microbes from the culture of catheter tip, &gt; 15 CFU&#xD;
      according to semi-quantitative method or &gt; 1000 CFU according to quantitative method);&#xD;
      incidence of catheter exit site infection; occurrence of catheter related infections/sepsis&#xD;
      or other severe infection-related complications; safety profile evaluation: occurrence of&#xD;
      hypersensitivity to the dressing on the basis of local objectivity (erythema, edema, other)&#xD;
      or on that of patient symptoms (itch, burning sensation); relating to the device performance:&#xD;
      incidence of high/medium/low dressing edge lift, ability to visualize the catheter insertion&#xD;
      site, easiness of removal, easiness of dressing application; incidence of unscheduled&#xD;
      dressing change. The study hypothesis implies that the use of slow release device containing&#xD;
      chlorhexidine may decrease the incidence of CRBSI. This has already been showed for&#xD;
      chlorhexidine impregnated sponges. Scope of the study is to verify if this property is also&#xD;
      true for TegaDerm CHG,which is a new chlorhexidine-releasing dressing in which the medication&#xD;
      is directly released by an integrated transparent gel pad, so that the catheter exit site&#xD;
      remains visible and easy to inspect without removing the dressing.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>October 2009</start_date>
  <completion_date type="Anticipated">October 2012</completion_date>
  <primary_completion_date type="Anticipated">April 2012</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of catheter-related bloodstream infection</measure>
    <time_frame>Up to 7 days after catheter removal</time_frame>
    <description>According to the definition of CRBSI suggested in &quot;Clinical practice guidelines for the diagnosis and management of intravascular catheter-related infection: 2009 update by the Infectious Diseases Society of America&quot; (Clin Infect Dis 2009; 49:1-45)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence of adverse events</measure>
    <time_frame>Up to 2 days after catheter removal</time_frame>
    <description>Other Secondary Outcome Measures are represented by: determining whether TegadermTM CHG decreases catheter colonization; determining whether TegadermTM CHG decreases the incidence of catheter site infection; evaluating patient comfort; to evaluate overall nursing satisfaction (ease of dressing application, incidence of dressing edge lift, ability to visualize the catheter insertion site, ease of removal); determining whether TegadermTM CHG decreases the incidence of unscheduled dressing change compared to the control group.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">1200</enrollment>
  <condition>Catheterization</condition>
  <condition>Infection</condition>
  <arm_group>
    <arm_group_label>TegaDerm CHG</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>TegaDerm CHG is the interventional arm to be compared with the control group in which the dressing is TegaDerm (without CHG).</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Transparent adhesive dressing with an integrated gel pad containing 2% w/w chlorhexidine gluconate (CHG) (TegaDerm CHG)</intervention_name>
    <description>The intervention is represented by the combination of the TegaDerm transparent adhesive dressing with an integrated gel pad containing 2% w/w chlorhexidine gluconate (CHG), an antiseptic agent with broad spectrum antimicrobial and antifungal activity.</description>
    <arm_group_label>TegaDerm CHG</arm_group_label>
    <other_name>TegaDerm CHG</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age ≥ 18 years&#xD;
&#xD;
          -  Hospitalized patients, either in Intensive Care Unit or in non-Intensive Care ward&#xD;
             settings&#xD;
&#xD;
          -  Clinical indication for the insertion of a non-tunneled central venous catheter&#xD;
             (excluding large bore catheters for dialysis or pheresis) or a PICC&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Age &lt; 18 years&#xD;
&#xD;
          -  Inability to obtain an informed consent&#xD;
&#xD;
          -  Actual evidence - or recent history (&lt; 30 days) - of bloodstream infection&#xD;
&#xD;
          -  Central lines inserted in the femoral vein&#xD;
&#xD;
          -  Central lines inserted by surgical cutdown&#xD;
&#xD;
          -  Use of so called 'treated' catheters, i.e. catheters whose internal and/or external&#xD;
             surface is coated with antibacterial drugs as well as catheters whose polyurethane&#xD;
             releases ions with potential antiseptic action, should be excluded by the present&#xD;
             protocol&#xD;
&#xD;
          -  Specific intolerance or known hypersensitivity to transparent dressings or to&#xD;
             chlorhexidine&#xD;
&#xD;
          -  Any form of dermatitis, burns, skin lesions or tattoos at the insertion site&#xD;
&#xD;
          -  Burns over ≥ 15% of the body surface area&#xD;
&#xD;
          -  Use of topical antibiotics within a 10cm of the catheter insertion site&#xD;
&#xD;
          -  Enrollment in another investigational drug or device study at any time during this&#xD;
             study or 30 days prior.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Giancarlo Scoppettuolo, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Dpt. Infectious Diseases, Rome Catholic University (CUSacredHeart)</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Mauro Pittiruti, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Dpt. Surgery, Rome Catholic University (CUSacredHeart)</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Giancarlo Scoppettuolo, MD</last_name>
    <phone>+393498380576</phone>
    <email>g.scoppettuolo@rm.unicatt.it</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Mauro Pittiruti, MD</last_name>
    <phone>+393388514032</phone>
    <email>mauro.pittiruti@rm.unicatt.it</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>I.C.U. Ospedale Civico</name>
      <address>
        <city>Palermo</city>
        <state>PA</state>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Zina Picciuca, RN</last_name>
      <email>zina@ospedalecivicopa.org</email>
    </contact>
    <investigator>
      <last_name>Zina Picciuca, RN</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Dpt. Infectious Diseases, Rome Catholic University</name>
      <address>
        <city>Rome</city>
        <state>RM</state>
        <zip>00168</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Giancarlo Scoppettuolo, MD</last_name>
      <phone>+393498380576</phone>
      <email>g.scoppettuolo@rm.unicatt.it</email>
    </contact>
    <contact_backup>
      <last_name>Laura Dolcetti, RN</last_name>
      <phone>+393336157080</phone>
      <email>laura.dolcetti@libero.it</email>
    </contact_backup>
    <investigator>
      <last_name>Laura Dolcetti, RN</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Giancarlo Scoppettuolo, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>I.C.U. Rome Catholic University</name>
      <address>
        <city>Rome</city>
        <state>RM</state>
        <zip>00168</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Vincenzo Mencio, RN</last_name>
      <email>vincenzomencio@interfree.it</email>
    </contact>
    <investigator>
      <last_name>Vincenzo Mencio, RN</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>General Surgery Policlinico Umberto I</name>
      <address>
        <city>Rome</city>
        <state>RM</state>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Susanna Sodo, RN</last_name>
      <email>s.sodo@policlinicoumberto1.it</email>
    </contact>
    <investigator>
      <last_name>Susanna Sodo, RN</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>I.C.U. Heart Surgery Policlinico Umberto I</name>
      <address>
        <city>Rome</city>
        <state>RM</state>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Susanna Sodo, RN</last_name>
      <email>s.sodo@policlinicoumberto1.it</email>
    </contact>
    <investigator>
      <last_name>Susanna Sodo, RN</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>I.C.U. Neurosurgery Policlinico Umberto I</name>
      <address>
        <city>Rome</city>
        <state>RM</state>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Susanna Sodo, RN</last_name>
      <email>s.sodo@policlinicoumberto1.it</email>
    </contact>
    <investigator>
      <last_name>Susanna Sodo, RN</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>I.C.U. Policlinico Umberto I</name>
      <address>
        <city>Rome</city>
        <state>RM</state>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Susanna Sodo, RN</last_name>
      <email>s.sodo@policlinicoumberto1.it</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Palliative Car Unit - Ospedale di Circolo</name>
      <address>
        <city>Varese</city>
        <state>VA</state>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Daniele Bertollo, MD</last_name>
      <email>dani.fabi@tin.it</email>
    </contact>
    <investigator>
      <last_name>Daniele Bertollo, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <link>
    <url>http://www.3m.com/</url>
    <description>Related Info</description>
  </link>
  <verification_date>January 2012</verification_date>
  <study_first_submitted>May 24, 2010</study_first_submitted>
  <study_first_submitted_qc>June 11, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 14, 2010</study_first_posted>
  <last_update_submitted>January 31, 2012</last_update_submitted>
  <last_update_submitted_qc>January 31, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 1, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Catholic University of the Sacred Heart</investigator_affiliation>
    <investigator_full_name>Giancarlo Scoppettuolo</investigator_full_name>
    <investigator_title>MD</investigator_title>
  </responsible_party>
  <keyword>Catheter-related bloodstream infections</keyword>
  <keyword>Chlorhexidine</keyword>
  <keyword>Transparent dressings</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infections</mesh_term>
    <mesh_term>Communicable Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Chlorhexidine</mesh_term>
    <mesh_term>Chlorhexidine gluconate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

